Targeting cell signalling pathways to fight the flu: Towards a paradigm change in anti-influenza therapy

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 1, 2009, Pages 1-4

  Ludwig, Stephan ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Cellular drug targets; Drug development; Influenza virus; Resistance; Signalling pathways

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ACETYLSALICYLIC ACID; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; M2 ION CHANNEL BLOCKER; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OSELTAMIVIR; RAF PROTEIN; SC 75441; SC 75741; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIVIRAL ACTIVITY; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; GENE EXPRESSION; INFLUENZA; INFLUENZA VIRUS A H5N1; NONHUMAN; PHARMACOLOGICAL BLOCKING; SIGNAL TRANSDUCTION; TARGET CELL DESTRUCTION; TRANSCRIPTION INITIATION; TREATMENT INDICATION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INFLUENZA, HUMAN; NF-KAPPA B; ORTHOMYXOVIRIDAE; SIGNAL TRANSDUCTION;

EID: 67249156976     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp161     Document Type: Editorial

References (38)

1. Nichol KL, Lind A, Margolis KL et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333: 889-93.
2. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992; 176: 119-30.
3. Hayden F. Developing new antiviral agents for influenza treatment: What does the future hold? Clin Infect Dis 2009; 48 Suppl 1: S3-13.
4. Bright RA, Shay DK, Shu B et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295: 891-4.
5. De Clercq E, Neyts J. Avian influenza A (H5N1) infection: Targets and strategies for chemotherapeutic intervention. Trends Pharmacol Sci 2007; 28: 280-5.
6. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000; 355: 827-35.
7. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007; 12: 603-16.
8. Kiso M, Mitamura K, Sakai-Tagawa Y et al. Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. Lancet 2004; 364: 759-65.
9. Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis 2008; 21: 626-38.
10. Ludwig S, Pleschka S, Planz O et al. Ringing the alarm bells: signalling and apoptosis in influenza virus infected cells. Cell Microbiol 2006; 8: 375-86.
11. Ludwig S. Exploited defense - how influenza virus takes advantage of antiviral signaling responses. Future Virology 2007; 2: 91-100.
12. Ludwig S, Planz O, Pleschka S et al. Influenza virus induced signaling pathways - targets for antiviral therapy? Trends Mol Med 2003; 9: 46-51.
13. Ludwig S. Influenza viruses and MAP kinase cascades - novel targets for antiviral therapy? Signal Transduction 2007; 7: 81-8.
14. Ludwig S, Planz O. Influenza viruses and the NF-κB signaling pathway - towards a novel concept of antiviral therapy. Biol Chem 2008; 389: 1307-12.
15. Widmann C, Gibson S, Jarpe MB et al. Mitogen-activated protein kinase: Conservation of a three-kinase module from yeast to human. Physiol Rev 1999; 79: 143-80.
16. Pleschka S, Wolff T, Ehrhardt C et al. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat Cell Biol 2001; 3: 301-5.
17. Ludwig S, Wolff T, Ehrhardt C et al. MEK inhibition impairs influenza B virus propagation without emergence of resistant variants. FEBS Lett 2004; 561: 37-43.
18. Olschlager V, Pleschka S, Fischer T et al. Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice. Oncogene 2004; 23: 6639-46.
19. Marjuki H, Alam MI, Ehrhardt C et al. Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase Cα-mediated activation of ERK signaling. J Biol Chem 2006; 281: 16707-15.
20. Planz O, Pleschka S, Ludwig S. MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells. J Virol 2001; 75: 4871-7.
21. Sebolt-Leopold JS, Dudley DT, Herrera R et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5: 810-16.
22. Cohen P. Protein kinases - the major drug targets of the twentyfirst century? Nat Rev Drug Discov 2002; 1: 309-15.
23. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999; 18: 6853-66.
24. Chu WM, Ostertag D, Li ZW et al. JNK2 and IKKß are required for activating the innate response to viral infection. Immunity 1999; 11: 721-31.
25. Wurzer WJ, Ehrhardt C, Pleschka S et al. NF-κB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation. J Biol Chem 2004; 279: 30931-7.
26. Nimmerjahn F, Dudziak D, Dirmeier U et al. Active NF-κB signalling is a prerequisite for influenza virus infection. J Gen Virol 2004; 85: 2347-56.
27. Wurzer WJ, Planz O, Ehrhardt C et al. Caspase 3 activation is essential for efficient influenza virus propagation. EMBO J 2003; 22: 2717-28.
28. Faleiro L, Lazebnik Y. Caspases disrupt the nuclear - cytoplasmic barrier. J Cell Biol 2000; 151: 951-9.
29. Kramer A, Liashkovich I, Oberleithner H et al. Apoptosis leads to a degradation of vital components of active nuclear transport and a dissociation of the nuclear lamina. Proc Natl Acad Sci USA 2008; 105: 11236-41.
30. Pauli EK, Schmolke M, Wolff T et al. Influenza A virus inhibits type I IFN signaling via NF-κB-dependent induction of SOCS-3 expression. PLoS Pathog 2008; 4: E1000196.
31. Wei L, Sandbulte MR, Thomas PG et al. NFκB negatively regulates interferon-induced gene expression and anti-influenza activity. J Biol Chem 2006; 281: 11678-84.
32. Kumar N, Xin ZT, Liang Y et al. NF-κB signaling differentially regulates influenza virus RNA synthesis. J Virol 2008; 82: 9880-9.
33. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 1998; 396: 77-80.
34. Mazur I, Wurzer WJ, Ehrhardt C et al. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-κB-inhibiting activity. Cell Microbiol 2007; 9: 1683-94.
35. Sunden Y, Park CH, Matsuda K et al. The effects of antipyretics on influenza virus encephalitis in mice and chicks. J Vet Med Sci 2003; 65: 1185-8.
36. Boriskin YS, Leneva IA, Pecheur EI et al. Arbidol: A broadspectrum antiviral compound that blocks viral fusion. Curr Med Chem 2008; 15: 997-1005.
37. Droebner K, Ehrhardt C, Poetter A et al. CYSTUS052, a polyphenol-rich plant extract, exerts anti-influenza virus activity in mice. Antiviral Res 2007; 76: 1-10.
38. Ehrhardt C, Hrincius ER, Korte V et al. A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. Antiviral Res 2007; 76: 38-47.